NCT05050149Phase 2Completed

Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations

Study sponsor: Palvella Therapeutics, Inc. · PVLA

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2022-11-15Actual
Enrollment · participants12Actual
Source updated2025-01-17Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview